We provide the datasets used in this study. The datasets include: (1) incidence rates of hPIV associated ALRI (see "ALRI" file); (2) hospitalisation rates of hPIV associated ALRI (see "Hos" file); (3)
Recently, new technologies have emerged for the prevention of respiratory syncytial virus (RSV) infections. Reliable epidemiological data are essential for accurately assessing the disease burden and
aEstimates were weighted using the adjusted sample weight for this sample, WTH1N1. bAssuming no pre-existing seropositivity at baseline. cAge-standardized to the U.S. Census Bureau population estimate
Estimates exclude the proportion of the incidence envelope attributable to “other pathogens”, because these were not considered in Approach 1 (applied to 60 countries within EURO, AMRO sub-region A, a
